



**WEDNESDAY, 9<sup>th</sup> NOVEMBER 2016 COMMENCING 9:30 AM**  
**AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST**  
**LLANEDYRN, CARDIFF, CF23 9XF**

## **AGENDA**

- |                                       |                  |
|---------------------------------------|------------------|
|                                       | <b>Enclosure</b> |
| 1. <b>Welcome and introduction</b>    |                  |
| 2. <b>Apologies</b>                   |                  |
| 3. <b>Declarations of interest</b>    |                  |
| 4. <b>Minutes of previous meeting</b> | 1/AWMSG/1116     |

***To protect commercial confidentiality the following appraisal will be held in private***

- |  |                            |
|--|----------------------------|
| 5. <b>Appraisal 1: Full Submission (WPAS)</b><br><b>Levofloxacin (Quinsair<sup>®</sup>)</b> for the management of chronic pulmonary infections due to <i>Pseudomonas aeruginosa</i> in adult patients with cystic fibrosis | 2/AWMSG/1116<br>Appendices |
| 6. <b>Appraisal 2: Instructed Appraisal (WPAS)</b><br><b>Sofosbuvir/velpatasvir (Epclusa<sup>®</sup>)</b> for the treatment of chronic hepatitis C virus (HCV) infection in adults   | 3/AWMSG/1116<br>Appendices |

***The meeting will now open to the public (approximately 11.00am)***

- |   |                            |
|---|----------------------------|
| 7. <b>Chairman's report (verbal update)</b>   |                            |
| 8. <b>Vitamins for Babies, Children and Pregnant and Breastfeeding Women</b>  | 4/AWMSG/1116               |
| 9. <b>Review of existing advice:</b><br><b>Insulin detemir (Levemir<sup>®</sup>)</b> for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.  | 5/AWMSG/1116               |
| 10. <b>Appraisal 3: Full Submission</b><br><b>Aviptadil/phentolamine (Invicorp<sup>®</sup>)</b> for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology | 6/AWMSG/1116<br>Appendices |
| 11. <b>National Prescribing Indicators 2016–2017 – Analysis of Prescribing Data to June 2016</b>  | 7/AWMSG/1116               |

12. **Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG – Data to March 2016** 8/AWMSG/1116
13. **Appraisal 4: Limited Submission**  
**Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey®)** for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load  $\leq$  100,000 HIV 1 RNA copies/mL 9/AWMSG/1116  
Appendices
14. **Appraisal 5: Full Submission**  
**Dequalinium chloride (Fluomizin®)** for the treatment of bacterial vaginosis 10/AWMSG/1116  
Appendices
15. **Feedback from AWPAG Meeting held 28<sup>th</sup> September 2016** 11/AWMSG/1116